An open framework quantifying the multi-dimensional value of real-time, multilingual respiratory-outbreak surveillance for pharma — across supply chain, market access, medical affairs and commercial readiness.
Lead-time gains over traditional surveillance, supply and demand alignment, payer evidence, government-affairs positioning, and the asymmetric cost of being late.